Christopher R. Flowers

The University of Texas MD Anderson Cancer Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

3.2Author DataRank

Indexed papers

5in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 5 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes

American Journal of Hematology(2024)10.1002/ajh.27202

Top 10%

2.1DataRank

Top 10%24 citations

Matthew J. Maurer, Brian K. Link, Andrew L. Feldman, Thomas M. Habermann, David L. Jaye +38 more

Papers

Driven by 82 papers — median percentile 51. Top paper: “Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial”.

Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial

Nature Medicine(2024)10.1038/s41591-023-02785-8

N/A

4.0DataRank · unranked

468 citations

Ye Li, Rafet Başar, Hind Rafei, May Daher, Jinzhuang Dou +31 more

Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma

Blood Cancer Discovery(2022)10.1158/2643-3230.bcd-21-0177

N/A

3.4DataRank · unranked

75 citations

David M. Swoboda, Uri Greenbaum, Junsheng Ma, Romil Patel, Kartik Devashish +34 more

Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma

Journal of Clinical Oncology(2021)10.1200/jco.21.01797

N/A

2.5DataRank · unranked

83 citations

Shuangtao Zhao, Hun Ju Lee, Holly A. Hill, Chi Young Ok, Rashmi Kanagal‐Shamanna +22 more

The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes

American Journal of Hematology(2024)10.1002/ajh.27202

Top 10%

2.1DataRank

Top 10%24 citations

Matthew J. Maurer, Brian K. Link, Andrew L. Feldman, Thomas M. Habermann, David L. Jaye +38 more

TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma

Molecular Cancer(2022)10.1186/s12943-022-01655-0

N/A

2.1DataRank · unranked

76 citations

Dapeng Hao, Preetesh Jain, Yijing Li, Qingsong Cai, Yixin Yao +14 more

Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma

Journal of Clinical Oncology(2022)10.1200/jco.22.00597

N/A

1.7DataRank · unranked

58 citations

R. Eric Davis, Lei Feng, Fredrick B. Hagemeister, Raphaël Steiner, Hun Ju Lee +24 more

Clustering of cutaneous T‐cell lymphoma is associated with increased levels of the environmental toxins benzene and trichloroethylene in the state of Georgia

Cancer(2020)10.1002/cncr.32665

N/A

1.5DataRank · unranked

31 citations

A. Rana Bayakly, Kevin C. Ward, Mohammad K. Khan, Shuo Chen, Mary Jo Lechowicz +4 more

Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial

The Lancet Oncology(2022)10.1016/s1470-2045(21)00638-0

N/A

1.5DataRank · unranked

56 citations

Preetesh Jain, Shuangtao Zhao, Hun Ju Lee, Loretta J. Nastoupil, Luis Fayad +32 more

Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society

CA A Cancer Journal for Clinicians(2020)10.3322/caac.21628

N/A

1.0DataRank · unranked

953 citations

Andrew M. D. Wolf, Timothy R. Church, Ruth Etzioni, Christopher R. Flowers, Abbe Herzig +13 more

A single-cell atlas of CD19 chimeric antigen receptor T cells

Cancer Cell(2023)10.1016/j.ccell.2023.08.015

Top 21%

0.969DataRank

Top 21%24 citations

Jared Henderson, Max J. Gordon, Irtiza Sheikh, Loretta J. Nastoupil, Jason R. Westin +8 more

SETD2 Haploinsufficiency Enhances Germinal Center–Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis

Cancer Discovery(2022)10.1158/2159-8290.cd-21-1514

N/A

0.896DataRank · unranked

30 citations

Matt Teater, Ceyda Durmaz, Cem Meydan, Alexandra G. Chivu, Amy Chadburn +14 more

Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial

The Lancet Haematology(2024)10.1016/s2352-3026(24)00133-9

N/A

0.833DataRank · unranked

29 citations

Jie Xu, Manoop S. Bhutani, Paolo Strati, Penny Q Fang, Susan Wu +22 more

Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response

Haematologica(2022)10.3324/haematol.2022.281954

N/A

0.822DataRank · unranked

15 citations

Sushanth Gouni, Jason R. Westin, Lei Feng, Haleigh Mistry, Raphaël Steiner +16 more

PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity

Blood(2022)10.1182/blood.2021011597

N/A

0.738DataRank · unranked

136 citations

Shuhua Wang, Kevin Z. Chen, Alexandra Waller, Aditi Sharma, Claudia L. Edgar +14 more

A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL

Blood Advances(2022)10.1182/bloodadvances.2022008174

N/A

0.629DataRank · unranked

15 citations

Stefan Alig, Yasuhiro Oki, Loretta J. Nastoupil, Luis Fayad, Sattva S. Neelapu +16 more

Gene expression profiling-based risk prediction and profiles of immune infiltration in diffuse large B-cell lymphoma

Blood Cancer Journal(2021)10.1038/s41408-020-00404-0

N/A

0.574DataRank · unranked

45 citations

Kritika Subramanian, Turgay Ayer, Johan Van Weyenbergh, Andrés Chang, Jean L. Koff +2 more

Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma

Journal of Clinical Oncology(2025)10.1200/jco-25-00925

N/A

0.520DataRank · unranked

31 citations

Gilles Salles, Laurie H. Sehn, Alex F. Herrera, Jonathan W. Friedberg, Marek Trněný +32 more

In-depth analysis of SARS-CoV-2–specific T cells reveals diverse differentiation hierarchies in vaccinated individuals

JCI Insight(2022)10.1172/jci.insight.156559

N/A

0.505DataRank · unranked

28 citations

Muharrem Müftüoğlu, Shaoheng Liang, Mahesh Basyal, Jiangxing Lv, Mehmet Emin Akdogan +5 more

The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma

Experimental Hematology and Oncology(2024)10.1186/s40164-024-00484-9

N/A

0.494DataRank · unranked

26 citations

Changying Jiang, Alexa A Jordan, Yuxuan Che, Yang Liu, Qingsong Cai +18 more

Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.8011

N/A

0.470DataRank · unranked

22 citations

Fateeha Furqan, Jason R. Westin, Luis Fayad, Sairah Ahmed, Hun Ju Lee +15 more

Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma

Blood Cancer Journal(2023)10.1038/s41408-023-00927-2

N/A

0.425DataRank · unranked

16 citations

Krystle Nomie, Nikita Kotlov, VitaIy Segodin, Holly A. Hill, Chi Young Ok +8 more

Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐GemOx: A Multicenter Cohort Study

American Journal of Hematology(2025)10.1002/ajh.27630

N/A

0.409DataRank · unranked

10 citations

Jean L. Koff, Melissa C. Larson, Brad S. Kahl, Carla Casulo, Izidore S. Lossos +25 more

Venous thromboembolism risk in cancer patients receiving first‐line immune checkpoint inhibitor versus chemotherapy

American Journal of Hematology(2023)10.1002/ajh.26954

N/A

0.406DataRank · unranked

14 citations

Sarah May, Jennifer La, Kylee L. Martens, Christopher I. Amos, Christopher R. Flowers +7 more

B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS

Cancer Epidemiology Biomarkers & Prevention(2022)10.1158/1055-9965.epi-21-0875

N/A

0.389DataRank · unranked

7 citations

Claire M. Vajdic, Martha S. Linet, Susan L. Slager, Jenna Voutsinas, Alexandra Nieters +38 more

Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T Therapy

JAMA Network Open(2025)10.1001/jamanetworkopen.2025.3455

N/A

0.373DataRank · unranked

11 citations

Rishab Prakash, Paul Edelkamp, Mark Knafl, Anath C. Lionel, Ranjit Nair +94 more

Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy

Haematologica(2023)10.3324/haematol.2023.284453

N/A

0.284DataRank · unranked

4 citations

Naishu Kui, Ryan Sun, Jason R. Westin, Raphaël Steiner, Ranjit Nair +16 more

Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial

Nature Communications(2025)10.1038/s41467-025-62509-z

N/A

0.241DataRank · unranked

4 citations

Lei Feng, Jason R. Westin, Ranjit Nair, Luis Fayad, Maria Alma Rodriguez +14 more

A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma

Blood Advances(2025)10.1182/bloodadvances.2025016483

N/A

0.241DataRank · unranked

4 citations

Lei Feng, Jason R. Westin, Fredrick B. Hagemeister, Hun Ju Lee, Luis Fayad +16 more

PD-1 expression identifies proliferating malignant CLL B cells and is a potential biomarker of response to BTK inhibitor therapy

Proceedings of the National Academy of Sciences(2025)10.1073/pnas.2426935122

N/A

0.165DataRank · unranked

2 citations

Adam Pelletier, Donald J. McGuire, Maria Tsagiopoulou, Maria Karipidou, Amy Ayers +13 more

Clinical outcomes of patients with newly diagnosed large B-cell lymphoma in a safety-net hospital system

Blood Neoplasia(2024)10.1016/j.bneo.2024.100020

Top 78%

0.104DataRank

Top 78%1 citations

Chijioke Nze, Danielle Guffey, Rock Bum Kim, Abiodun Oluyomi, Omar Rosales +11 more

Therapy for patients with POD24 follicular lymphoma: Treatment patterns and outcomes from the Lymphoma Epidemiology of Outcomes (LEO) Consortium.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.7573

N/A

0.104DataRank · unranked

1 citations

Melissa C. Larson, Jonathan R Day, Thomas M. Habermann, Izidore S. Lossos, Yucai Wang +15 more

Early-Stage Extranodal NK/T-Cell Lymphoma, Nasal Type: A Role for Elective Nodal Irradiation?

Advances in Radiation Oncology(2024)10.1016/j.adro.2024.101650

N/A

0.104DataRank · unranked

1 citations

Sonal S. Noticewala, Susan Wu, Jillian R. Gunther, Ethan B. Ludmir, L. Jeffrey Medeiros +15 more

CondiS web app: imputation of censored lifetimes for machine learning-based survival analysis

Bioinformatics(2022)10.1093/bioinformatics/btac461

N/A

0.104DataRank · unranked

1 citations

Christopher R. Flowers, Ziyi Li, Xuelin Huang, Yizhuo Wang

The Genetic Basis of Hepatosplenic T-cell Lymphoma

UNC Libraries(2020)10.17615/vdkf-4m21

N/A

0DataRank · unranked

0 citations

Wing C. Chan, Steven M. Horwitz, Eric D. Hsi, Anupama Reddy, Nicholas S. Davis +50 more

Adjunct Therapy with T Regulatory Cells Decreases Inflammation and Preserves the Anti-Tumor Activity of CAR T Cells

Cells(2023)10.3390/cells12141880

N/A

0DataRank · unranked

8 citations

Meixian Huang, Mi-Ae Lyu, Joseph D. Khoury, Sairah Ahmed, Krina K. Patel +8 more

The impact of a multidisciplinary goals-of-care program on unplanned readmission rates at a comprehensive cancer center

Supportive Care in Cancer(2023)10.1007/s00520-023-08265-6

N/A

0DataRank · unranked

5 citations

Clark R. Andersen, Kaycee Wilson, Nico Nortjé, Marina George, Christopher R. Flowers +3 more

MASH: Mediation Analysis of Survival Outcome and High-dimensional Omics Mediators with Application to Complex Diseases

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.08.22.554286

N/A

0DataRank · unranked

4 citations

Christopher R. Flowers, Ziyi Li, Xuelin Huang, Peng Wei, Sunyi Chi

Six Years Follow up of Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hyper CVAD/MTX in Patients (age ≤ 65 years) with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-1 Clinical Trial

Blood(2023)10.1182/blood-2023-181312

N/A

0DataRank · unranked

1 citations

Hun Ju Lee, Jason R. Westin, Loretta J. Nastoupil, Luis Fayad, Ranjit Nair +14 more

Data from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression

(2023)10.1158/2643-3230.c.6550995

Top 100%

0DataRank

Top 100%0 citations

Qing Deng, Mario L. Marques‐Piubelli, Enyu Dai, Minghao Dang, Man Chun John +29 more

Data from Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma

(2023)10.1158/2643-3230.c.6550812.v1

N/A

0DataRank · unranked

0 citations

David M. Swoboda, Uri Greenbaum, Junsheng Ma, Romil Patel, Kartik Devashish +34 more

The IMPACT of an interdisciplinary goals-of-care program on readmission rates at a comprehensive care center.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.6565

N/A

0DataRank · unranked

0 citations

Clark R. Andersen, Kaycee Wilson, Nico Nortjé, Marina George, Christopher R. Flowers +3 more

Genomic and Transcriptomic Profiles of Blastoid and Pleomorphic Mantle Cell Lymphoma Are Distinct from Classic Histology Mantle Cell Lymphoma

Blood(2023)10.1182/blood-2023-181319

N/A

0DataRank · unranked

0 citations

Holly A. Hill, Chi Young Ok, Alexander Nesmalov, Vitaly Segodin, Dmitry Tabakov +13 more

A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib

Blood(2023)10.1182/blood-2023-188051

N/A

0DataRank · unranked

0 citations

Meixian Huang, Sharon Bledsoe, Naveen Pemmaraju, Tapan M. Kadia, Prithviraj Bose +10 more

Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET–CT-documented First Remission

Clinical Lymphoma Myeloma & Leukemia(2020)10.1016/j.clml.2020.02.008

N/A

0DataRank · unranked

5 citations

Jillian R. Gunther, Penny Fang, Sarah A. Milgrom, Brinda Rao Korivi, Corey T. Jensen +16 more

Defining primary refractory large B-cell lymphoma

Blood Advances(2024)10.1182/bloodadvances.2024012760

N/A

0DataRank · unranked

32 citations

Raphael Mwangi, Yucai Wang, Arushi Khurana, Matthew J. Maurer, Amy Ayers +15 more

Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial

The Lancet Haematology(2020)10.1016/s2352-3026(20)30067-3

N/A

0DataRank · unranked

29 citations

John P. Leonard, Thomas E. Witzig, Thomas M. Habermann, Kristie A. Blum, Nancy L. Bartlett +8 more

Thrombosis risk prediction in lymphoma patients: A multi‐institutional, retrospective model development and validation study

American Journal of Hematology(2024)10.1002/ajh.27335

N/A

0DataRank · unranked

8 citations

Jennifer La, Kaitlin N. Swinnerton, Danielle Guffey, Raka Bandyo, Giordana De Las Pozas +11 more

Maintenance Therapy for Cutaneous T-cell Lymphoma After Total Skin Electron Irradiation: Evidence for Improved Overall Survival With Ultraviolet Therapy

Clinical Lymphoma Myeloma & Leukemia(2020)10.1016/j.clml.2020.06.020

N/A

0DataRank · unranked

10 citations

Jeffrey M. Switchenko, Mary Jo Lechowicz, Natia Esiashvili, Christopher R. Flowers, Mohammad K. Khan +2 more

Stiffness based enrichment of leukemia cells using microfluidics

APL Bioengineering(2020)10.1063/1.5143436

N/A

0DataRank · unranked

12 citations

Abhishek Raj, Brynn McFarland, Hannah Brink, Jordan C. Ciciliano, Meredith E. Fay +7 more

Translating prognostic quantification of c-MYC and BCL2 from tissue microarrays to whole slide images in diffuse large B-cell lymphoma using deep learning

Diagnostic Pathology(2024)10.1186/s13000-023-01425-6

N/A

0DataRank · unranked

6 citations

Muhammad Khalid Khan Niazi, Andrew L. Feldman, David L. Jaye, Christopher R. Flowers, Lee Cooper +2 more

MASH: Mediation analysis of survival outcome and high-dimensional omics mediators with application to complex diseases

The Annals of Applied Statistics(2024)10.1214/23-aoas1838

N/A

0DataRank · unranked

6 citations

Christopher R. Flowers, Ziyi Li, Xuelin Huang, Peng Wei, Sunyi Chi

Neighborhood-level social determinants of health burden among adolescent and young adult cancer patients and impact on overall survival

JNCI Cancer Spectrum(2024)10.1093/jncics/pkae062

N/A

0DataRank · unranked

5 citations

Tori Tonn, Midhat Z. Jafry, Sairah Ahmed, Branko Cuglievan, J. Andrew Livingston +7 more

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis

Blood(2024)10.1182/blood.2024025681

N/A

0DataRank · unranked

5 citations

Matthew J. Maurer, Thomas M. Habermann, Richard Burack, Jennifer R. Chapman, Jonathon B. Cohen +18 more

Impact of patient demographics and neighborhood socioeconomic variables on clinical trial participation patterns for NHL

Blood Advances(2024)10.1182/bloodadvances.2023011040

N/A

0DataRank · unranked

6 citations

Clark R. Andersen, Amy Ayers, Jason R. Westin, Michael Wang, Swaminathan P. Iyer +10 more

American Society of Hematology: building a comprehensive minority recruitment and retention professional program

Blood Advances(2024)10.1182/bloodadvances.2024013519

N/A

0DataRank · unranked

2 citations

Rahma Warsame, Melody Smith, Arturo Molina, Rayne H. Rouce, Belinda R. Avalos +11 more

CASi: A framework for cross-timepoint analysis of single-cell RNA sequencing data

Scientific Reports(2024)10.1038/s41598-024-58566-x

N/A

0DataRank · unranked

1 citations

Christopher R. Flowers, Michael Wang, Xuelin Huang, Ziyi Li, Yizhuo Wang

Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Blood(2024)10.1182/blood-2024-205196

N/A

0DataRank · unranked

4 citations

Dai Chihara, Luis Fayad, Sattva S. Neelapu, Sairah Ahmed, Frederick Hagemeister +11 more

Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes after CAR T-Cell Therapy for Lymphoma

Blood(2024)10.1182/blood-2024-207616

N/A

0DataRank · unranked

1 citations

Sushanth Gouni, Lei Feng, Charles Gaulin, Amrit S. Gonugunta, Turçin Saridogan +22 more

Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma

Blood(2024)10.1182/blood-2024-206042

N/A

0DataRank · unranked

1 citations

Chi Young Ok, Jason R. Westin, Holly A. Hill, Ranjit Nair, Swaminathan P. Iyer +28 more

Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma

Blood(2024)10.1182/blood-2024-208300

N/A

0DataRank · unranked

0 citations

Naishu Kui, Ryan Sun, Eslam Aboismail, Sanjit O. Tewari, Ajlan Al Zaki +26 more

Interim PET-Adapted De-Escalation Chemotherapy Regimen for Advanced Stage Classical Hodgkin Lymphoma Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine: Phase 2 Safety and Efficacy Study

Blood(2024)10.1182/blood-2024-212005

N/A

0DataRank · unranked

0 citations

Gregory Ravizzini, Eslam Aboismail, Jenna M. Wixom, Jared Henderson, Luis Fayad +11 more

Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel

Blood Advances(2025)10.1182/bloodadvances.2024014476

N/A

0DataRank · unranked

10 citations

Lubna Rehman, Abdur Rehman, Faezeh Darbaniyan, Donna M. Weber, Melody Becnel +21 more

TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma

Blood(2025)10.1182/blood.2024026919

N/A

0DataRank · unranked

7 citations

Qingsong Cai, Yang Liu, Lei Nie, Heng‐Huan Lee, Fangfang Yan +24 more

Genetic heterogeneity of diffuse large B-cell lymphoma

UNC Libraries(2020)10.17615/dkye-0q87

N/A

0DataRank · unranked

23 citations

Gopesh Srivastava, Leon Bernal‐Mizrachi, Eric D. Hsi, Katherine Walsh, Magdalena Czader +27 more

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma

Journal of Clinical Oncology(2025)10.1200/jco-25-00892

N/A

0DataRank · unranked

1 citations

Vít Procházka, Tarec Christoffer El‐Galaly, Christopher R. Flowers, Diego Villa, Emmanuel Bachy +43 more

Impact of sociodemographic determinants on enrollment into contemporary lymphoma clinical trials: a systematic review

The Oncologist(2025)10.1093/oncolo/oyaf180

N/A

0DataRank · unranked

1 citations

Ang Li, Alexis Romero, Christopher R. Flowers, Chijioke Nze, Jun Yang Jiang

271 | LEUKEMIC NON‐NODAL MANTLE CELL LYMPHOMA IS NOT NECESSARILY EQUIVALENT TO INDOLENT MCL: A REPORT FROM THE LEO COHORT STUDY

Hematological Oncology(2025)10.1002/hon.70094_271

N/A

0DataRank · unranked

0 citations

Yihua Chen, Jeffrey M. Switchenko, Suheil Albert Atallah‐Yunes, Georgio Pongas, Mary P. Watkins +16 more

29 | A COMPARATIVE ANALYSIS OF HISTOLOGIC TRANSFORMATION OF FOLLICULAR LYMPHOMA AT DIAGNOSIS (COMPOSITE LYMPHOMA) AND SEQUENTIALLY TRANSFORMED FOLLICULAR LYMPHOMA

Hematological Oncology(2025)10.1002/hon.70093_29

N/A

0DataRank · unranked

0 citations

Melissa C. Larson, Jonathan Day, Urshila Durani, Mazie Tsang, Dai Chihara +22 more

233 | S1608: RANDOMIZED PHASE II TRIAL COMPARING LENALIDOMIDE/OBINUTUZUMAB AND UMBRALISIB/OBINUTUZUMAB WITH CHEMOIMMUNOTHERAPY IN EARLY PROGRESSING FOLLICULAR LYMPHOMA (POD24)

Hematological Oncology(2025)10.1002/hon.70094_233

N/A

0DataRank · unranked

0 citations

H. Li, Heiko Schöder, Alex F. Herrera, Richard Burack, Brian K. Link +10 more

Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2025-012401

N/A

0DataRank · unranked

0 citations

Amanda Brandt, Anath C. Lionel, Jared Henderson, Jason R. Westin, Sherry Adkins +9 more

Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study

The Lancet Haematology(2022)10.1016/s2352-3026(22)00033-3

N/A

0DataRank · unranked

64 citations

Melissa C. Larson, Julianne J. Lunde, Thomas M. Habermann, Izidore S. Lossos, Yucai Wang +19 more

Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy

JAMA Network Open(2020)10.1001/jamanetworkopen.2020.13935

N/A

0DataRank · unranked

12 citations

Jillian R. Gunther, Penny Fang, Mikaela Bankston, Sarah A. Milgrom, David Boyce-Fappiano +14 more

Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials

The Lancet(2022)10.1016/s0140-6736(22)01390-3

N/A

0DataRank · unranked

68 citations

Ruitao Lin, Christopher R. Flowers, Shanda Finnigan, Lisa M. Cordes, Yoko Fukuda +7 more

Clonal hematopoiesis is associated with increased toxicity in large B-cell lymphoma patients treated with chimeric antigen receptor T cell therapy

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.09.28.461858

N/A

0DataRank · unranked

0 citations

David M. Swoboda, Uri Greenbaum, Jungsheng Ma, Romil Patel, Kartik Devashish +32 more

Influenza Vaccination Rates Among Patients With a History of Cancer: Analysis of the National Health Interview Survey

Open Forum Infectious Diseases(2021)10.1093/ofid/ofab198

N/A

0DataRank · unranked

19 citations

Mallory K. Ellingson, Christopher R. Flowers, Robert A. Bednarczyk, Andrés Chang

Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy

Blood Advances(2021)10.1182/bloodadvances.2021004765

N/A

0DataRank · unranked

41 citations

Jeffrey M. Switchenko, Diego Villa, Kami J. Maddocks, Michael C. Churnetski, Alina S. Gerrie +30 more

Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma

Blood Advances(2022)10.1182/bloodadvances.2022009225

N/A

0DataRank · unranked

11 citations

Jeffrey M. Switchenko, Veronika Bachanová, James N. Gerson, Stefan K. Barta, Max J. Gordon +30 more

Herpes simplex virus lymphadenitis is associated with tumor reduction in a patient with chronic lymphocytic leukemia

Journal of Clinical Investigation(2022)10.1172/jci161109

N/A

0DataRank · unranked

6 citations

Anton M. Sholukh, Andreas Wieland, David L. Jaye, Mary Carrington, Meei‐Li Huang +11 more

Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems

Journal of Clinical Oncology(2023)10.1200/jco.22.01542

N/A

0DataRank · unranked

72 citations

Jennifer La, Sarah May, Danielle Guffey, Wilson Luiz da Costa, Christopher I. Amos +16 more

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma

Journal of Clinical Investigation(2023)10.1172/jci165694

N/A

0DataRank · unranked

35 citations

Yang Liu, Junwei Lian, Shengjian Huang, Alexa A Jordan, Qingsong Cai +16 more

External validation of a novel electronic risk score for cancer‐associated thrombosis in a comprehensive cancer center

American Journal of Hematology(2023)10.1002/ajh.26928

N/A

0DataRank · unranked

18 citations

Giordana De Las Pozas, Clark R. Andersen, Chijioke Nze, Katy M. Toale, Emily M. Milner +7 more

Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma

Nature Communications(2021)10.1038/s41467-021-22872-z

N/A

0DataRank · unranked

68 citations

Changying Jiang, Guangchun Han, Dapeng Hao, Junwei Lian, Yang Liu +33 more

Christopher R. Flowers

Indexed papers

Top data-sharing exemplar

Papers